Treatment of chronic HCV infection in special populations

International Journal of Medical Sciences

Volumn 3, Issue 2, 2006, Pages 69-74

  Hoefs, John ^a,c   Aulakh, Vikramjit S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MERCY HOSPITAL AND MEDICAL CENTER   (United States)

^c Building 53   (United States)

Author keywords

African American; Cirrhosis; Fatty liver; HCV; Non responder; Treatment HCV

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

AFRICAN AMERICAN; DOSE RESPONSE; FATIGUE; FATTY LIVER; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KINETICS; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; OBESITY; POSTOPERATIVE PERIOD; PREVALENCE; REVIEW; TREATMENT RESPONSE;

EID: 33646265748     PISSN: 14491907     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.3.69     Document Type: Review

References (37)

1. Sallie R. Replicative Homeostasis: A fundamental mechanism mediating selective viral replication and escape mutation. Virol J. 2005; 2: 10-23
2. Chisari FV. Unscrambling hepatitis C virus-host interactions. Nature 2005; 436(7053): 930-2
3. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic Hepatitis C virus infection. Nature 2005; 436(7053): 946-52.
4. Tang KH, Herrmann E, et al. Relationship between early HCV kinetics and T-cell reactivity in Chronic Hepatitis C genotype 1 during peginterferon and ribavirin therapy. J Heptol. 2005; 43(5): 776-82
5. Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. Journal of Antimicrobial chemotherapy, 2004; 53:15-18
6. Asahina Y, Izumi N et al. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol. 2005; 43(4): 623-9.
7. Sanchez-Tapias JM et al. Sustained virological response after prolonged treatment with peginterferon alfa-2a (40KD) and ribavirin in treatment- naïve patients with chronic hepatitis C and detectable HCV RNA after week 4 of therapy: TERAVIC-4 study. In: Poster abstracts presented at 39th Annual Meeting of the European Association for the Study of the Liver; April 14-18, 2004; Berlin, Germany
8. von Wagner M, Huber M, Berg T et al. Peginterferon alpha 2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005; 129(2): 522-7
9. Zeuzem S, Buti M, Ferenci P, el al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol. 2006;44(1):97-103.
10. Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis. 2004;189(6):964-70.
11. Bacon BR, McHutchison JG. Treatment issues with chronic hepatitis C: special populations and pharmacy strategies. Am J Manag Care. 2005;11:S296-306
12. Howell C, Jeffers L, Hoofnagle JH. Hepatitis C in African Americans: summary of a workshop. Gastroenterology. 2000;119:1385-1396.
13. Jeffers LJ, Cassidy W, Howell CD, et al. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology. 2004;39:1702-1708.
14. Heathcote EJ, Pockros PJ, Fried MW, et al. The pharmacokinetics of pegylated-40K interferon alfa-2a (PEG-IFN) in chronic hepatitis C (CHC) patients with cirrhosis. Gastroenterology. 1999;116(4):737.
15. Torriani FJ, Rodriguez-Torres M, Rockstroh JK. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351(5):438-450.
16. Graham CS, Baden LR, Yu E. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a metaanalysis. Clin Infect Dis. 2001;33:562-569.
17. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34:395-403.
18. Terrault NA. Treatment of recurrent hepatitis C in liver transplant recipients. Clinical Gastroenterol Hepatol. 2005; 10:S125-31
19. Lee W, Dieterich D. Challenges in the management of HIV and hepatitis C virus infection. Drugs. 2004;64(7):693-700
20. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with Human Immunodeficiency Virus infection. Clin Infect Dis. 2001;32:492-497.
21. Oldakowska-Jedynak U, Paczek L. The course of hepatitis C infection after liver transplantation. Pol Merkuriusz Lek. 2005; 19(110): 220-4.
22. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology. 2005;42(2):255-62
23. Shiffman ML, Di Bisceglie AM, Lindsay KL. Peginterferon slfa-2a ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004;126:1015-1023.
24. Everson E, Schiffman M, Hoefs J, et al. Quantitative liver function tests predict sustained virologic response to retreatment with peginterferon alfa-2a plus ribavirin: results of the lead-in phase of the halt-C trial. Hepatology 2004; 40:313A.
25. Everson E, Hoefs J, Malet P. Impaired virologic response in patients with advanced liver disease due to chronic hepatitis C is independently linked to severity of disease: results from the Halt C Trial. Hepatology 2004; 40: 180A.
26. Harrison SA, Brunt EM, Oliver DA, et al. The presence of severe steatosis or steatohepatitis impairs response to antiviral therapy in patients with chronic hepatitis C. Hepatology. 2003;38(1):A626.
27. Bruno R, Sacchi P et al. Viral dynamics and pharmacokinetics of peginterferonalpha-2a and peginterferon alpha-2b in naïve patients with chronic hepatitis C: a randomized, controlled study. Antivir Ther. 2004; 9(4): 491-7
28. Enriquez J, Gallego A, Torras X, Perez-Olmeda T, Diago M, Soriano V, Lujan MS, Garcia-Samaniego J. Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. J Viral Hepat. 2000 ;7(6):403-8.
29. Sethi A, Shiffman ML. Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response. MD consults core collection. Clinics in Liver Disease 2005; 9: 453
30. Horvath G, Stotz G et al. The effect of long term and high dose interferon treatment in chronic hepatitis C. Pathol Oncol Res. 1996;291: 59-62
31. Kaiser S et al. Successful retreatment of chronic hepatitis C patients with a nonresponse to standard interferon/ribavirin using daily consensus interferon and ribavirin. In: 55th AASLD Abstract 173 (poster); October 29-November 2, 2004; Boston, MA.
32. Dimarco V, Vaccaro A, Ferraro D et al. High dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C. Alimentary pharmacology and therapeutics 2001,15: 953-958
33. Leevy CB, Chalmers CP et al. Comparison of African American and Non African American patients SVR for PEG-IFN alpha 2 + weight based ribavirin non-responders retreated with IFN alpha + weight based ribavirin. In: AASLD Abstract 172; Oct 29- Nov 2, 2004; Boston, Massachusetts.
34. Diago et al. High dose peginterferon alfa 2a (40KD) and ribavirin in patients infected with hepatitis C virus genotype 1 who failed to respond to interferon alfa and ribavirin. Abstract Hepatology, 2003, 38: 740-741
35. Gitlin N, Muther KD. Sustained viral response with peginterferon alpha 2a and ribavirin in patients with chronic hepatitis C who were non-responders to peginterferon alpha 2b and ribavirin. In: AASLD (Abstract 413); Oct 29- Nov 2 2004; Boston, MA.
36. Gross JB et al. Renew Trial- High dose re-treatment with peginterferon alpha 2b plus ribavirin for non responders in chronic HCV patients. In: AASLD 2003 (Abstract 321); Oct 24-28 2003; Boston , MA.
37. Malet P, et al. The Target Trial- Final result using 3.0μg/kg pegylated Interferon alpha 2b plus ribavirin for chronic hepatitis C patients who were non-responders and relapsers to previous therapy. In: AASLD presentation; Nov 15 2005; CA, US.